Early Experience With Teprotumumab for Chronic Thyroid Eye Disease | oneGRAVESvoice

welcome to oneGRAVESvoice

- a positively charged Graves' disease and thyroid eye disease community.
  • join today!
Scientific Articles

Early Experience With Teprotumumab for Chronic Thyroid Eye Disease

key information

source: American Journal of Ophthalmology Case Reports

year: 2020

authors: Daniel J.Ozzello, Don O.Kikkawa, Bobby S.Kornab


To report the first case of a patient with chronic thyroid eye disease (TED) treated with teprotumumab.

A 50-year-old female with a 3-year history of Graves’ disease presented with bilateral exophthalmos greatest on the left side. She was followed for 2 years with stable proptosis measurements (23mm OD, 28mm OS). Her clinical activity score (CAS) was 1 and there were no examination findings reflective of active inflammation. The patient underwent systemic treatment with teprotumumab and despite chronic TED and low CAS, she had notable improvement in proptosis (18mm OD, 22mm OS) and decrease in extraocular muscle volume as noted on orbital imaging.

Conclusion and Importance:
This case report suggests that teprotumumab may be used in patients with chronic TED and low CAS. Improvement in the proptosis and reduction in extraocular muscle volume suggest that teprotumumab may alter disease course even in patients with inactive or quiescent TED.

organization: UC San Diego Viterbi Family Department of Ophthalmology, USA; UC San Diego Department of Surgery, USA

DOI: 10.1016/j.ajoc.2020.100744